Jerome Niquet1,2, Roger Baldwin2, Keith Norman2, Lucie Suchomelova2, Lucille Lumley3, Claude G Wasterlain1,2,4. 1. Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A. 2. Epilepsy Research Laboratory (151), Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, U.S.A. 3. US Army Medical Research Institute of Chemical Defense (USAMRICD), Aberdeen Proving Ground, Maryland, U.S.A. 4. Brain Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.
Abstract
OBJECTIVE: Pharmacoresistance remains an unsolved therapeutic challenge in status epilepticus (SE) and in cholinergic SE induced by nerve agent intoxication. SE triggers a rapid internalization of synaptic γ-aminobutyric acid A (GABAA ) receptors and externalization of N-methyl-d-aspartate (NMDA) receptors that may explain the loss of potency of standard antiepileptic drugs (AEDs). We hypothesized that a drug combination aimed at correcting the consequences of receptor trafficking would reduce SE severity and its long-term consequences. METHODS: A severe model of SE was induced in adult Sprague-Dawley rats with a high dose of lithium and pilocarpine. The GABAA receptor agonist midazolam, the NMDA receptor antagonist ketamine, and/or the AED valproate were injected 40 min after SE onset in combination or as monotherapy. Measures of SE severity were the primary outcome. Secondary outcomes were acute neuronal injury, spontaneous recurrent seizures (SRS), and Morris water maze (MWM) deficits. RESULTS: Midazolam-ketamine dual therapy was more efficient than double-dose midazolam or ketamine monotherapy or than valproate-midazolam or valproate-ketamine dual therapy in reducing several parameters of SE severity, suggesting a synergistic mechanism. In addition, midazolam-ketamine dual therapy reduced SE-induced acute neuronal injury, epileptogenesis, and MWM deficits. SIGNIFICANCE: This study showed that a treatment aimed at correcting maladaptive GABAA receptor and NMDA receptor trafficking can stop SE and reduce its long-term consequences. Early midazolam-ketamine dual therapy may be superior to monotherapy in the treatment of benzodiazepine-refractory SE. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
OBJECTIVE: Pharmacoresistance remains an unsolved therapeutic challenge in status epilepticus (SE) and in cholinergic SE induced by nerve agent intoxication. SE triggers a rapid internalization of synaptic γ-aminobutyric acid A (GABAA ) receptors and externalization of N-methyl-d-aspartate (NMDA) receptors that may explain the loss of potency of standard antiepileptic drugs (AEDs). We hypothesized that a drug combination aimed at correcting the consequences of receptor trafficking would reduce SE severity and its long-term consequences. METHODS: A severe model of SE was induced in adult Sprague-Dawley rats with a high dose of lithium and pilocarpine. The GABAA receptor agonist midazolam, the NMDA receptor antagonist ketamine, and/or the AED valproate were injected 40 min after SE onset in combination or as monotherapy. Measures of SE severity were the primary outcome. Secondary outcomes were acute neuronal injury, spontaneous recurrent seizures (SRS), and Morris water maze (MWM) deficits. RESULTS:Midazolam-ketamine dual therapy was more efficient than double-dose midazolam or ketamine monotherapy or than valproate-midazolam or valproate-ketamine dual therapy in reducing several parameters of SE severity, suggesting a synergistic mechanism. In addition, midazolam-ketamine dual therapy reduced SE-induced acute neuronal injury, epileptogenesis, and MWM deficits. SIGNIFICANCE: This study showed that a treatment aimed at correcting maladaptive GABAA receptor and NMDA receptor trafficking can stop SE and reduce its long-term consequences. Early midazolam-ketamine dual therapy may be superior to monotherapy in the treatment of benzodiazepine-refractory SE. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Nicolas Gaspard; Brandon Foreman; Lilith M Judd; James N Brenton; Barnett R Nathan; Blathnaid M McCoy; Ali Al-Otaibi; Ronan Kilbride; Ivan Sánchez Fernández; Lucy Mendoza; Sophie Samuel; Asma Zakaria; Giridhar P Kalamangalam; Benjamin Legros; Jerzy P Szaflarski; Tobias Loddenkemper; Cecil D Hahn; Howard P Goodkin; Jan Claassen; Lawrence J Hirsch; Suzette M Laroche Journal: Epilepsia Date: 2013-06-12 Impact factor: 5.864
Authors: Brenda M Marrero-Rosado; Marcio de Araujo Furtado; Erica R Kundrick; Katie A Walker; Michael F Stone; Caroline R Schultz; Donna A Nguyen; Lucille A Lumley Journal: Epilepsy Behav Date: 2020-06-20 Impact factor: 2.937
Authors: Lucille Lumley; Dennis Miller; William T Muse; Brenda Marrero-Rosado; Marcio de Araujo Furtado; Michael Stone; Jeffrey McGuire; Christopher Whalley Journal: Epilepsia Open Date: 2019-06-18
Authors: Haiyu Liu; Kurt R Stover; Nila Sivanenthiran; Jonathan Chow; Chloe Cheng; Yapeng Liu; Stellar Lim; Chiping Wu; Donald F Weaver; James H Eubanks; Hongmei Song; Liang Zhang Journal: Front Pharmacol Date: 2019-09-24 Impact factor: 5.810